BRIEF—Genetic Immunity expands deal with JSC Pharmadis

US biotech Genetic Immunity is expanding a collaboration with JSC Pharmadis, granting licenses for 20 cancer indications for products created using its transdermally delivered pDNA-based vaccine technology.

In 2018, Pharmadis licensed an HIV vaccine derived from the Genetic Immunity’s DermaVir immunotherapy vaccine platform. The technology uses a novel plasmid DNA that encodes disease specific antigens.

Under terms of the new deal, Pharmadis receives rights to market products under all twenty cancer indications in Russia. The firms will work together to develop the vaccines and gain approval. Upon approval Genetic Immunity will be eligible for double-digit royalties on sales.